Janssen-Cilag, a Johnson & Johnson company, Receives CHMP Nod for RYBREVANT® in First-Line NSCLC Treatment with EGFR Exon 20 Insertion Mutations

Janssen-Cilag International NV, a company under the umbrella of Johnson & Johnson, has announced a significant milestone in the treatment landscape for non-small cell lung cancer (NSCLC). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of RYBREVANT® (amivantamab) in combination with chemotherapy for adult patients with advanced NSCLC harboring activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as a first-line treatment option. This recommendation follows promising results from the PAPILLON study, which showcased improved progression-free survival when amivantamab was used alongside chemotherapy compared to chemotherapy alone.